Skip to main content
. Author manuscript; available in PMC: 2015 Jul 1.
Published in final edited form as: Pain. 2014 Apr 13;155(7):1346–1355. doi: 10.1016/j.pain.2014.04.011

Fig. 1. Timeline of administered treatments used in this study.

Fig. 1

The COMT inhibitor OR486 or vehicle was administered in the presence or absence of the β2- and β3-adrenergic receptor antagonists ICI118,551 and SR59320A, the NO synthase inhibitor L-NAME, or neutralizing antibodies against TNFα, IL-1β , IL-6, or CCL2.